Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Financiadora de Estudos e Projetos (FINEP)
Information provided by (Responsible Party):
Oswaldo Cruz Foundation
ClinicalTrials.gov Identifier:
NCT01154049
First received: June 29, 2010
Last updated: October 30, 2013
Last verified: October 2013

June 29, 2010
October 30, 2013
March 2011
April 2014   (final data collection date for primary outcome measure)
Safety of the vaccine [ Time Frame: 4 months after the first dose ] [ Designated as safety issue: Yes ]
Safety and tolerability of the vaccine (sm14 antigen plus GLA adjuvant) against schistosomiasis in health adults
Same as current
Complete list of historical versions of study NCT01154049 on ClinicalTrials.gov Archive Site
  • Proportion of seroconversion [ Time Frame: 30 days after the third vaccine dose ] [ Designated as safety issue: No ]
    Proportion of seroconversion for sm14 antigen 30 days after the complete vaccinal schedule (3 doses, 30 days apart)
  • Cellular immune response to sm-14 vaccination in health adults [ Time Frame: 30 days after the third vaccine dose ] [ Designated as safety issue: No ]
    Determine the cellular immune responses and their correlation to the development and magnitude of humoral responses
Same as current
Not Provided
Not Provided
 
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis

This is a phase I, open-label, single arm trial, which aims to assess the safety of the vaccine prepared sm14 in healthy subjects. The product immunogenicity will be evaluated by conducting serology (anti-sm14 antibodies) and testing of cellular response to the antigen by the method ELI-SPOT. Each participant will remain in the study for approximately 4 months. The total study duration is 10 months, considering a period of 6 months for inclusion. Will be included in the study subjects male and female, between 18 and 49 years, that manifest their will to participate in the research by signing an Informed Consent Form. Eligible population for the study are subjects who do not present at screening significant changes in renal, cardiac and liver functions, complete blood count, clotting, present no acute or chronic illnesses, are not in the chronic use of any medication, do not have HIV infection or other immunodeficiency. Pregnant or breastfeeding women will not be included. Volunteers will receive three doses of vaccine prepared sm14, in doses containing 50 mcg of the antigen, associated with adjuvant GLA-SE at a dose of 10 mcg, with an interval of 30 days between each application. Twenty volunteers will be included in the study. This is a convenience sample, established for the first test of the product in humans, for the initial safety assessment.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Schistosomiasis
Biological: sm14 antigen plus adjuvant GLA
Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
Experimental: single arm
3 doses of the vaccine, on days 0, 30 and 60.
Intervention: Biological: sm14 antigen plus adjuvant GLA
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged between 18 and 49 years.
  • Available for follow-up throughout the study period (approximately 120 days).
  • Ability to understand and sign the informed consent form (IC).
  • HIV serology negative
  • Absence of helminth infections in general (nematodes, cestodes and trematodes, among which Schistosoma mansoni) at the inclusion in the study.
  • Patients who has not chronic use or have not used in the past 45 days any medication, except trifling as nasal saline and vitamins.
  • Be in good health without significant medical history.
  • Screening physical examination without clinical significant abnormalities.
  • Screening laboratory tests without significant abnormalities according to normal standards and the evaluation of investigators.
  • Additional criteria for females of childbearing potential: Negative pregnancy test at screening; consistent use of contraceptive methods (male or female condom, diaphragm, IUD and oral contraceptives or "patches").

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Use of cytotoxic or immunosuppressive drugs in the last six months, except for spray nasal corticosteroids for allergic rhinitis or topical corticosteroids for uncomplicated dermatitis.
  • Immunoglobulin use 60 days prior to vaccination.
  • Use of any type of vaccine 30 days prior to vaccination.
  • Plan to receive any other vaccine during the period of participation in the study (four months)
  • Use any type of investigational medication in a period of 30 days prior to vaccination
  • Use of allergy shots with antigens within 14 days prior to vaccination.
  • Psychiatric illness that hinders adherence to the protocol, such as psychosis, obsessive-compulsive neurosis, bipolar disorder treatment, diseases that require treatment with lithium, and suicide thoughts in the last 5 years prior to inclusion.
  • Presence of neurological disease, liver disease or kidney disease (diseases which have led to hospitalization or prolonged treatment).
  • History of sickle cell anemia.
  • Asplenia (no spleen or its removal).
  • History of alcohol use/abuse (CAGE criterion) or illicit drugs.
  • Blood pressure above 140/90 mmHg at screening or hypertension requiring drug treatment.
  • Coagulopathy diagnosed by a doctor or report of capillary fragility (eg, bruising, bleeding, etc.) after injections or blood sampling.
  • Active malignancy (eg, any type of cancer) or treated so it may relapse during the study.
  • History of allergy to vaccines containing adjuvants composed of lipids (GLA or MPL)
Both
18 Years to 49 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Brazil
 
NCT01154049
sm14-CT001P1
Yes
Oswaldo Cruz Foundation
Oswaldo Cruz Foundation
Financiadora de Estudos e Projetos (FINEP)
Principal Investigator: Marilia S Oliveira, MD, MsC Instituto de Pesquisa Clínica Evandro Chagas (IPEC)
Oswaldo Cruz Foundation
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP